Nanotechnology Now

Our NanoNews Digest Sponsors

Heifer International

Wikipedia Affiliate Button

Home > Press > CRO and EDC Companies Launch Partnership and Deliver Integrated Solutions for Medical Device Companies Conducting Clinical Research

Abstract:
Pleiad Devices Joins OmniComm's CRO Preferred ProgramTM and Chooses the TrialMasterTM Electronic Data Capture (EDC) Solution Exclusively for Clinical Trials

CRO and EDC Companies Launch Partnership and Deliver Integrated Solutions for Medical Device Companies Conducting Clinical Research

FT. LAUDERDALE, FL | Posted on March 12th, 2008

OmniComm Systems, Inc. (OTCBB: OMCM), a leader in integrated electronic data capture (EDC) solutions for clinical trials, today announced that after extensive evaluation of the industry's leading EDC systems, Pleiad Devices has chosen OmniComm as its preferred EDC vendor. Pleiad is an international Medical Device Contract Research Organization (CRO) with offices located in Europe and the US. The company's primary focus is providing clinical trial support services for medical device companies. As part of the partnership with OmniComm, Pleiad will take full advantage of the flexible, intuitive and robust EDC solution, TrialMaster, in an upcoming ophthalmology trial.

"Pleiad's clinical research team has years of experience in designing, organizing and managing clinical projects for medical device companies," said Stephen Brandao, Vice President of Business Development for Pleiad Devices. "Over the years, our team has had experience with most of the EDC vendors in the marketplace. TrialMaster is one of the best EDC products that we have seen and we look forward to offering our medical device customers this premier service."

The team of clinical professionals at Pleiad Devices specializes in clinical research support specifically for medical device companies. The company understands the regulatory issues in North America and Europe and provides quality clinical research services that serve regulatory, marketing and reimbursement clinical research needs internationally. Pleiad ensures compliance with all FDA and EU clinical research regulations so that all clinical data meet the regulatory standards of the major medical device markets. The clinical team offers expertise in a wide variety of areas including endovascular surgery, orthopedics, gynecology, tissue ablation, ophthalmology, combination products, drug delivery technologies and nanotechnology.

"Our CRO Preferred Program offers companies like Pleiad a true partner that will deliver the ancillary services that CROs need to be competitive in the evaluation process such as co-marketing and sales support for EDC. We offer the consummate partnership, both comprehensive company support and delivery of a first class EDC product," said Stephen Johnson, Executive Vice President of Business Development, Services and Client Services and Support. "At OmniComm, we are confident that our partnerships with CROs like Pleiad will ensure quality deliverables for the clinical research clients that we serve."

####

About OmniComm Systems, Inc.
OmniComm Systems, Inc. (www.OmniComm.com) provides customer-driven Internet solutions to pharmaceutical, biotechnology, research and medical device organizations that conduct life changing clinical trial research. OmniComm's growing base of satisfied customers is a direct result of the company's commitment to deliver products and services that ensure ease of use, faster study build, ease of integration and better performance. OmniComm's client intuitive pricing model allows companies that range from small to mid-size to large scale institutions to safely and efficiently capitalize on their clinical research investments.

OmniComm ranked in the top 150 as one of the fastest revenue growth technology companies in North America during the last 5 years. OmniComm Systems, Inc. has corporate headquarters in Ft. Lauderdale, Florida with offices in Bonn, Germany, Tula, Russia, California, Maryland, New York, North Carolina and Texas.

Safe Harbor Disclaimer

Statements about OmniComm's future expectations, including without limitation, future revenues and earnings, plans and objectives for the future operations, future agreements, future economic performance, operations and all other statements in this press release other than historical facts are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Securities Litigation Reform Act of 1995. OmniComm intends that such forward-looking statements be subject to the Safe Harbors created thereby. Since these statements involve risks and uncertainties, including but not limited to economic competitive, governmental, contractual and technological factors affecting OmniComm's operations, markets and profitability, actual results could differ materially and adversely from the expected results.

For more information, please click here

Contacts:
Lizanne Kelley
OmniComm Systems, Inc.
954-473-1254 Extension 283

Copyright © Marketwire

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Fast, efficient sperm tails inspire nanobiotechnology December 5th, 2016

Journal Nanotechnology Progress International (JONPI) Volume 6, issue 2 coming out soon! December 5th, 2016

Infrared instrumentation leader secures exclusive use of Vantablack coating December 5th, 2016

Construction of practical quantum computers radically simplified: Scientists invent ground-breaking new method that puts quantum computers within reach December 5th, 2016

Nanomedicine

Fast, efficient sperm tails inspire nanobiotechnology December 5th, 2016

Journal Nanotechnology Progress International (JONPI) Volume 6, issue 2 coming out soon! December 5th, 2016

UTSA study describes new minimally invasive device to treat cancer and other illnesses: Medicine diffusion capsule could locally treat multiple ailments and diseases over several weeks December 3rd, 2016

Nanobiotix Provides Update on Global Development of Lead Product NBTXR3: Seven clinical trials across the world: More than 2/3 of STS patients recruited in the “act.in.sarc” Phase II/III trial: Phase I/II prostate cancer trial now recruiting in the U.S. November 28th, 2016

Announcements

Fast, efficient sperm tails inspire nanobiotechnology December 5th, 2016

Journal Nanotechnology Progress International (JONPI) Volume 6, issue 2 coming out soon! December 5th, 2016

Infrared instrumentation leader secures exclusive use of Vantablack coating December 5th, 2016

Construction of practical quantum computers radically simplified: Scientists invent ground-breaking new method that puts quantum computers within reach December 5th, 2016

Alliances/Trade associations/Partnerships/Distributorships

Infrared instrumentation leader secures exclusive use of Vantablack coating December 5th, 2016

Leti and Grenoble Partners Demonstrate World’s 1st Qubit Device Fabricated in CMOS Process: Paper by Leti, Inac and University of Grenoble Alpes Published in Nature Communications November 28th, 2016

Mechanism for sodium storage in 2-D material: Tin selenide is an effective host for storing sodium ions, making it a promising material for sodium ion batteries October 27th, 2016

Enterprise In Space Partners with Sketchfab and 3D Hubs for NewSpace Education October 13th, 2016

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project